Biogen Idec Inc. (BIIB)
-NasdaqGS 225.18 
1.67(0.74%) 4:00PM EDT|After Hours
:
225.16 0.02 (0.01%) 4:38PM EDT - Nasdaq Real Time Price
| Prev Close: | 226.85 |
|---|
| Open: | 226.05 |
|---|
| Bid: | 224.05 x 100 |
|---|
| Ask: | 225.16 x 100 |
|---|
| 1y Target Est: | 220.11 |
|---|
| Beta: | 1.29 |
|---|
| Next Earnings Date: | 22-Jul-13 |
|---|
| Day's Range: | 224.33 - 234.46 |
|---|
| 52wk Range: | 126.39 - 234.46 |
|---|
| Volume: | 1,274,066 |
|---|
| Avg Vol (3m): | 1,371,540 |
|---|
| Market Cap: | 53.45B |
|---|
| P/E (ttm): | 35.73 |
|---|
| EPS (ttm): | 6.30 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Royalty raises Elan bid, issues ultimatum to shareholdersat Reuters(Mon 3:27PM EDT)
- S&P 500 Growth Stocks Portfolio That Can Outperform The Market By A Big Marginat Seeking Alpha(Mon 2:59PM EDT)
- Analysts: J.C. Penney Is In Trouble and 3 More Research Notes to Browseat Wall St. Cheat Sheet(Mon 2:55PM EDT)
- Royalty Pharma increases bid for drugmaker ElanAP(Mon 2:33PM EDT)
- Royalty Pharma Raises Elan Bid to $12.50 a Shae in Cashat Bloomberg(Mon 12:01PM EDT)
- Biogen's Hemophilia BLA AcceptedZacks(Mon 9:40AM EDT)
- Multiple Sclerosis and Hemophilia: This Biotech's Just Getting Startedat Motley Fool(Sun, May 19)
- IBD 50: Top 5 Medical Stocks Include Celgene, Actavisat Investor's Business Daily(Sat, May 18)
- Data show new Roche leukemia drug may improve on Rituxanat Reuters(Thu, May 16)
- Investing in Health Care Innovation: A Wall Street Transcript Interview with Finny Kuruvilla, Portfolio Manager of the Eventide Gilead FundWall Street Transcript(Thu, May 16)
- AGN, LLY, BIIB, CELG And AMGN, Pushing Health Care Sector Downwardat TheStreet(Thu, May 16)
- 2 Scariest Dividend Stocks in Health Careat Motley Fool(Thu, May 16)
- Roche Experimental Leukemia Drug Helps Shrink Tumorsat Bloomberg(Thu, May 16)
- Data shows new Roche leukemia drug may improve on Rituxanat Reuters(Wed, May 15)
- Biogen Idec Inc (BIIB): Today's Featured Health Care Laggardat TheStreet(Wed, May 15)
Key Statistics
| Forward P/E (1 yr): | 22.72 |
|---|
| P/S (ttm): | 9.55 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | 8.04 |
|---|
| Quarterly EPS Est
(Jun-13)
: | 1.90 |
|---|
| Mean Recommendation*: | 2.1 |
|---|
| PEG Ratio (5 yr expected): | 1.53 |
|---|
Business Summary
Biogen Idec Inc. discovers, develops, manufactures, and markets therapies for the treatment of neurodegenerative diseases, hemophilia, and autoimmune disorders in the United States and internationally.
View More